Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Alphadent, Vi-One General, and Chlorhexidine Mouthwashes on Salivary Streptococcus
IRCT20240219061051N1Phase 3Completed
- Sponsor
- Kurdistan University of Medical Sciences
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of chlorhexidine in carious lesion (3 arms), sponsored by Kurdistan University of Medical Sciences. Primary endpoint: Change in salivary Streptococcus levels. Started Feb 2024; status: completed.
02
Drugs
chlorhexidine
03
Conditions
carious lesion
Beyond the preview
Go deeper on IRCT20240219061051N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240219061051N1.